Previous 10 | Next 10 |
Citius Pharmaceuticals ( NASDAQ: CTXR ) on Tuesday said it had held a pre-biologics license application (BLA) meeting with the U.S. FDA to discuss its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. "Based on the FDA's pre-B...
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma PR Newswire Biologics License Application (BLA) submission planned for the second half of 2022 CRANFORD, N.J. , ...
Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as e...
A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...
Late-stage biopharmaceutical company Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it plans to split into two separate publicly-traded entities. CTXR said it would form a new company focused on developing and commercializing its therapy I/ONTAK for the treatment of rare forms of canc...
Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company PR Newswire IPO with distribution of shares to Citius shareholders planned for 2H 2022 Citius would retain Mino-Lok and...
Citius Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference on May 24, 2022 PR Newswire CRANFORD, N.J. , May 18, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharma...
Citius Pharmaceuticals press release (NASDAQ:CTXR): Q2 GAAP EPS of -$0.05 beats by $0.02. Topline results of Phase 3 trial in cancer immunotherapy I/ONTAK consistent with prior formulation; BLA submission on track for 2H 2022. Mino-Lok Phase 3 trial expanded to include sites outside the&...
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update PR Newswire Mino-Lok ® Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed by end of 2022 Top...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond. AdvisorShares Pure U.S. Cannabis ETF ( MSOS ): This leading cannabis ETF offers exposure...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...